Ananda Developments Plc (AQSE:ANA) finance director Jeremy Sturgess-Smith discusses the company's focus on developing CBD-based therapies for complex inflammatory pain conditions at the Proactive One2One Investor Forum.
Sturgess-Smith noted the growing global issue of chronic pain, particularly in patients with multiple long-term health conditions, known as multi-morbidities. He highlighted the company’s use of CBD due to its multi-modal effects, citing preclinical studies that show promising results, such as reduced endometriosis lesions in animal models.
He detailed the company’s progress in clinical trials, including its phase two studies targeting chemotherapy-induced peripheral neuropathy and endometriosis. He also revealed Ananda's strategic focus on securing grant funding, with over £1 million secured for ongoing trials in partnership with Edinburgh University. He expressed confidence in CBD’s potential as a prescription treatment, an area yet to see approved therapies.
To protect its innovations, Ananda has filed for patent protection on its formulation methods. With promising early-stage data and a clear clinical pathway, Sturgess-Smith emphasised the company’s goal of advancing to phase three trials and out-licensing opportunities.
